| Name | Title | Contact Details |
|---|
The Broad Institute brings together a diverse group of individuals from across its partner institutions — undergraduate and graduate students, postdoctoral fellows, professional scientists, administrative professionals, and academic faculty. The culture and environment at the Broad is designed to encourage creativity and to engage all participants, regardless of role or seniority, in the mission of the Institute. Within this setting, researchers are empowered — both intellectually and technically — to confront even the most difficult biomedical challenges. The Institute`s organization is unique among biomedical research institutions. It encompasses three types of organizational units: core member laboratories, programs and platforms. Scientists within these units work closely together — and with other collaborators around the world — to tackle critical problems in human biology and disease.
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.
Our illuminating molecules enhances the doctors ability to see disease tissue clearly improving their ability to treat cancer, autoimmune and other diseases.
Eurofins is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.